12:00 AM
 | 
Sep 28, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tibolone cancer data

Researchers from the U.S. Department of Health and Human Service's Agency for Healthcare Research and Quality (AHRQ) performed a comparative effectiveness analysis showing that tamoxifen, raloxifene and tibolone reduced the incidence of invasive breast cancer in midlife and older women, but that each drug carries distinct potential harms. The evaluation of 29 clinical trials showed...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >